Market capitalization | $81.56m |
Enterprise Value | $-48.08m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.78 |
EV/Sales (TTM) EV/Sales | -72.85 |
P/S ratio (TTM) P/S ratio | 123.58 |
P/B ratio (TTM) P/B ratio | 0.61 |
Revenue growth (TTM) Revenue growth | -95.28% |
Revenue (TTM) Revenue | $660.00k |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
3 Analysts have issued a Ikena Oncology Inc forecast:
3 Analysts have issued a Ikena Oncology Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.66 0.66 |
95%
95%
|
|
Gross Profit | -0.05 -0.05 |
100%
100%
|
|
EBITDA | -64 -64 |
5%
5%
|
EBIT (Operating Income) EBIT | -64 -64 |
6%
6%
|
Net Profit | -60 -60 |
5%
5%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ikena Oncology, Inc. is a clinical stage biotechnology company. It discovers and develops patient directed, biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412 and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.
Head office | United States |
CEO | Mark Manfredi |
Employees | 43 |
Founded | 2016 |
Website | www.ikenaoncology.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.